A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

Not Applicable

Completed

• Conditions: Neuropathic Diabetic Ulcer - Foot

• Registration Number: NCT01060670
• Lead Sponsor: Integra LifeSciences Corporation

Brief Summary

The objective of this study is to evaluate the safety and efficacy of the INTEGRA® Dermal Regeneration Template for the treatment of diabetic foot ulcers located distal to the malleolus in subjects with diabetes mellitus, neuropathy, and without significantly compromised arterial circulation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-01-31
• Study First Submitted QC: 2010-01-31
• Study First Posted: 2010-02-02
• Study Start: 2010-04
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Results First Submitted: 2016-03-23
• Status Verified: 2016-07
• Results First Submitted QC: 2016-07-29
• Last Update Submitted: 2016-07-29
• Results First Posted: 2016-09-22
• Last Update Posted: 2016-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 545

Inclusion Criteria

• Type I or Type II diabetes mellitus

• Glycosylated hemoglobin, HbA1c, ≤ 12%

• Negative serum pregnancy test at screening for female participants of child-bearing potential

• Willing and able to maintain the required off-loading (as applicable for the location for the ulcer) and applicable dressing changes

• At least one DFU that met the following criteria:

  1. Ulcer was diagnosed as a full-thickness neuropathic DFU that was located distal to the malleolus (excluding ulcers between the toes but including those of the heel),
  2. Minimum 2-cm margin between the qualifying study ulcer and any other ulcers on the specified foot (post debridement),
  3. Area greater than or equal to 1 square centimeter and less than or equal to 12 square centimeters (post debridement at the time of randomization),
  4. Wagner grade 1 or 2,
  5. Depth less than or equal to 5 millimeters with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts,
  6. Duration of the study ulcer was at least 30 days at the time of the screening visit

• Adequate vascular perfusion of the affected limb

Exclusion Criteria

• Suspected or confirmed signs/symptoms of gangrene or wound infection on any part of the limb
• History of hypersensitivity to bovine collagen and/or chondroitin.
• Pregnancy
• Previous treatment under this clinical protocol
• Participation in another clinical trial involving a device or systematically administered investigational study drug or treatment within 30 days of the randomization visit.
• Receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, was known to interfere with, or affect the rate and quality of wound healing
• Any unstable condition or circumstance that could interfere with treatment regimen compliance
• Excessive lymphedema that could interfere with wound healing
• Unstable Charcot foot or Charcot with boney prominence
• Ulcers secondary to a disease other than diabetes
• Osteomyelitis with necrotic soft bone
• Chopart amputation
• History of bone cancer or metastatic disease of the affected limb, radiation therapy to the foot, or chemotherapy within the 12 months prior to randomization
• Treatment with wound dressings that include growth factors, engineered tissues, or skin substitutes within 30 days of randomization or scheduled to receive such treatment during the study
• Non-study ulcer requiring treatment that could not be treated during the study with moist wound therapy
• History of or intercurrent illnesses or conditions (other than diabetes) that would compromise the safety of the subject, or the normal wound healing process
• Employees or relatives of any member of the investigational site or sponsor
• Size of the study ulcer following debridement decreased by more than 30% during the run in period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Incidence of Complete Wound Closure	16 weeks	100% closure as assessed by the Investigator and confirmed at 2 consecutive treatment phase visits.

Secondary Outcome Measures

Name	Time	Method
Incidence of Ulcer Recurrence	12 weeks	Measures the incidence of ulcer recurrence at the site of the study ulcer during the follow up phase.
Change in Short Form Health Survey (SF-36) Quality of Life Metrics	Baseline and 16 weeks	Short Form Health Survey (SF-36)- Quality of Life Metrics. The SF-36 was utilized and the Physical Function and Bodily Pain subscales were norm-based, with a Mean = 50, SD = 10. Scores could theoretically range from 0 to 100, with higher scores indicating a better health status.
Time to Complete Wound Closure	16 weeks	Time to complete wound closure, as assessed by computerized planimetry.
Rate of Wound Closure	16 weeks	Rate of wound closure as assessed by computerized planimetry
Incidence of Complete Wound Closure	16 weeks	Percentage of subjects with complete wound closure of the study ulcer, as assessed by computerized planimetry, during the treatment phase.

Trial Locations

Locations (32)

Costal Clinical Research; 🇺🇸 Mobile, Alabama, United States

Stockdale Podiatry Group; 🇺🇸 Bakersfield, California, United States

Center for Clinical Research; 🇺🇸 Fresno, California, United States

Diabetic Foot and Wound Treatment Center; 🇺🇸 El Centro, California, United States

Sacramento Foot and Ankle Center; 🇺🇸 Fair Oaks, California, United States

Advanced Foot Care and Clinical Research Center; 🇺🇸 Fresno, California, United States

California School of Podiatry Medicine at Samuel Merritt University; 🇺🇸 Oakland, California, United States

Northern California Foot and Ankle Center; 🇺🇸 Santa Rosa, California, United States

Bay Pines VA Healthcare System; 🇺🇸 Bay Pines, Florida, United States

Advanced Pharma CR, LLC; 🇺🇸 Miami, Florida, United States

Scroll for more (22 remaining)